Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin b2 receptor activation in human heart

Journal of the American College of Cardiology

Volumn 29, Issue 7, 1997, Pages 1599-1606

  Morris, Susie D ^a   Yellon, Derek M ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B2 RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ARTICLE; DRUG EFFECT; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HEART MUSCLE CONTRACTILE FORCE; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; MEDIATOR RELEASE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REOXYGENATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; CAPTOPRIL; FEMALE; HEART; HEART ATRIA; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LISINOPRIL; MALE; MIDDLE AGED; RECEPTORS, BRADYKININ;

EID: 0030995611     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00087-9     Document Type: Article

References (47)

1. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
2. Effects of captopril on ischemic events after myocardial infarction. Circulation. 90:1994;1731-1738.
3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet. 343:1994;1115-1122.
4. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 345:1995;669-685.
5. Parratt JR. Cardioprotection by angiotensin converting enzyme inhibitors - the experimental evidence. Cardiovasc Res. 28:1994;183-189.
6. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat reversal by the bradykinin antagonist Hoe 140 . J Cardiovasc Pharmacol. 21:1993;996-1003.
7. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther. 270:1994;681-689.
8. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res. 27:1993;334-340.
9. Ehring T, Baumgart D, Krajcar M, Hummelgen M, Kompa S, Heusch G. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide. Circulation. 90:1994;1368-1385.
10. 2 receptor activation. J Am Coll Cardiol. 28:1996;1616-1622.
11. Walker DM, Walker JM, Pugsley WB, Pattison CW, Yellon DM. Preconditioning in isolated superfused human muscle. J Mol Cell Cardiol. 27:1995;1349-1357.
12. Goto M, Liu Y, Ardell JL, Cohen MV, Downey JM. Bradykinin limits myocardial infarction by protein kinase C activation and not by nitric oxide synthesis [abstract]. Circulation. 90:(Suppl I):1994;I-208.
13. Baumgarten C, Linz W, Kunkel G, Scholkens BA, Weimer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol. 108:1993;293-295.
14. Martorana PA, Kattenbach B, Briepohl G, Linz W, Scholkens BA. Reduction of infarct size by local angiotensin converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol. 182:1990;395-396.
15. Speechly-Dick ME, Grover GJ, Yellon DM. Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent potassium channel. Circ Res. 77:1995;1030-1035.
16. Moravec CS, Schluchter MD, Paranandi L, et al. Inotropic effects of angiotensin II on human cardiac muscle in vitro. Circulation. 82:1990;1973-1984.
17. Opie L. ACE Inhibitors - Scientific Basis for Clinical use. 2nd ed. 1992;177-197 Authors' Publishing House, New York.
18. Tomai F, Crea F, Gaspardone A, Versaci F, Eposito C, Chiariello L, Gioffre PA. Mechanisms of cardiac pain during coronary angioplasty. J Am Coll Cardiol. 22:1993;1892-1896.
19. Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI-4. Circulation. 91:1995;37-47.
20. Ottani F, Galvani M, Ferrini D, et al. Prodromal angina limits infarct size a role for ischemic preconditioning . Circulation. 91:1995;291-297.
21. Ikonomidis JS, Tumiati LC, Weisel RD, Mickle DAG, Li RK. Preconditioning human ventricular cardiomyocytes with brief periods of simulated ischemia. Cardiovasc Res. 28:1994;1285-1291.
22. Lasley RD, Anderson GM, Mentzer RM. Ischemic and hypoxic preconditioning enhance postischemic recovery of function in the rat heart. Cardiovasc Res. 27:1993;565-570.
23. Shizukuda Y, Mallet RT, Lee SC, Downey HF. Hypoxic preconditioning of ischemic canine myocardium. Cardiovasc Res. 26:1992;534-542.
24. Engleman DT, Watanabe M, Englman RM, et al. Hypoxic preconditioning preserves antioxidant reserve in the working rat heart. Cardiovasc Res. 29:1995;133-140.
25. Webster KA, Discher DJ, Bishopric NH. Cardioprotection in an in vitro model of hypoxic preconditioning. J Mol Cell Cardiol. 27:1995;453-458.
26. Jenkins DP, Pugsley WB, Yellon DM. Ischemic preconditioning in a model of global ischemia infarct size limitation, but no reduction in stunning . J Mol Cell Cardiol. 27:1995;1623-1632.
27. Cohen Mv, Liu GS, Downey JM. Preconditioning causes improved wall motion as well as smaller infarcts after transient coronary artery occlusion in rabbits. Circulation. 84:1991;341-349.
28. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic preconditioning protects remote virgin myocardium from subsequent coronary occlusion. Circulation. 87:1993;893-899.
29. Weimer G, Scholkens BA, Linz W. Endothelial protection by converting enzyme inhibitors. Cardiovasc Res. 28:1994;166-172.
30. Kimura E, Hasimoto K, Furukawa S, Hayakawa H. Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. Am Heart J. 85:1973;635-647.
31. Matsuki K, Shoji T, Yoshida S, et al. Sympathetically induced myocardial ischemia causes the heart to release plasma kinin. Cardiovasc Res. 21:1987;428-432.
32. Nolly H, Carbinin L, Scicli G, Carretero OA, Scicli G. A local kallikrein-kinin system is present in rat hearts. Hypertension. 23:1994;919-923.
33. Goto M, Liu XY, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 77:1995;611-621.
34. Sargent CA, Sleph PG, Dzwonczyk S, et al. Cardioprotection in ischemic rat hearts with the -SH containing angiotensin converting enzyme inhibitor zofenopril possible involvement of the ATP sensitive potassium channel . J Pharmacol Exp Ther. 265:1993;609-618.
35. Richard V, Ghaleh B, Berdeaux A, Giudicelli JF. Comparison of the effects of EXP3174, an angiotensin II antagonist, and enalaprilat on myocardial infarct size in anaesthetized dogs. Br J Pharmacol. 110:1993;969-974.
36. Daniel HB, Carson RR, Ballard KD, Thomas GR, Privitera PJ. Effects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol. 6:1984;1043-1047.
37. Liang C, Gavras H, Black J, Sherman LG, Hood WB. Renin-angiotensin system inhibition in acute myocardial infarction in dogs effect on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size . Circulation. 66:1982;1249-1255.
38. Miki T, Miura T, Shimamoto K, Urabe K, Sakamoto J, Iimura O. Do angiotensin converting enzyme inhibitors limit myocardial infarct size? Clin Exp Pharmacol Physiol. 20:1993;429-434.
39. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation. 65:1982;40-48.
40. 1 receptors and bradykinin receptors, which act via different G proteins, synergistically raises inositol 1,4,5-triphosphate and intracellular free calcium in DDT1 MF-2 smooth muscle cells. Proc Natl Acad Sci USA. 89:1992;7330-7334.
41. Linz W, Weimer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 47:1995;25-29.
42. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins kallikreins, kininogens, and kininases . Pharmacol Rev. 44:1992;1-80.
43. Liu GS, Stanley AWH, Downy JM. Cyclooxygenase products are not involved in the protection against myocardial infarction afforded by preconditioning in the rabbit. Am J Cardiovasc Pathol. 4:1992;157-164.
44. Woolfson RG, Patel VC, Nield GH, Yellon DM. Inhibition of nitric oxide synthesis reduces infarct size by an adenosine-dependent mechanism. Circulation. 91:1995;1545-1551.
45. 2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circ Res. 76:1995;773-780.
46. Bruton J, Goto M, Downey JM. Endogenous angiotensin II contributes to ischemic preconditioning [abstract]. J Mol Cell Cardiol. 27:1995;A43.
47. Liu Y, Tsuchida A, Cohen MV, Downey JM. Pre-treatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol. 27:1995;883-892.